Correlation between histological activity and endoscopic, clinical, and serologic activities in patients with ulcerative colitis

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Kim, Dae Bum ^a   Lee, Kang Moon ^a   Lee, Ji Min ^a   Chung, Yoon Yung ^a   Sung, Hea Jung ^a   Paik, Chang Nyol ^a   Chung, Woo Chul ^a   Jung, Ji Han ^a   Choi, Hyun Joo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL FEATURE; COLON BIOPSY; COLONOSCOPY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; ENDOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROCTITIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEROLOGY; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

EID: 84956955538     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/5832051     Document Type: Article

References (34)

1. D. Laharie, J. Filippi, X. Roblin, et al., "Impact of mucosal healing on long-termoutcomes in ulcerative colitis treated with infliximab: amulticenter experience, " Alimentary Pharmacology andTherapeutics, vol. 37, no. 10, pp. 998-1004, 2013.
2. T. Kobayashi, M. Naganuma, S. Okamoto, et al., "Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis, " Journal of Gastroenterology, vol. 45, no. 11, pp. 1129-1137, 2010.
3. M. Rutter, B. Saunders, K. Wilkinson, et al., "Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis, " Gastroenterology, vol. 126, no. 2, pp. 451-459, 2004.
4. S. Mazzuoli, F. W. Guglielmi, E. Antonelli, M. Salemme, G. Bassotti, and V. Villanacci, "Definition and evaluation of mucosal healing in clinical practice, " Digestive and Liver Disease, vol. 45, no. 12, pp. 969-977, 2013.
5. B. I. Korelitz and S. C. Sommers, "Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes, "The American Journal of Gastroenterology, vol. 64, no. 5, pp. 365-370, 1975.
6. C.-H. Florén, C. Benoni, and R. Willén, "Histologic and colonoscopic assessment of disease extension in ulcerative colitis, " Scandinavian Journal ofGastroenterology, vol. 22, no. 4, pp. 459-462, 1987.
7. R. B. Gupta, N. Harpaz, S. Itzkowitz, et al., "Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study, " Gastroenterology, vol. 133, no. 4, pp. 1099-1105, 2007.
8. S. P. L. Travis, P. D. R. Higgins, T. Orchard, et al., "Review article: defining remission in ulcerative colitis, " Alimentary Pharmacology andTherapeutics, vol. 34, no. 2, pp. 113-124, 2011.
9. L. Peyrin-Biroulet, A. Bressenot, and W. Kampman, "Histologic remission: the ultimate therapeutic goal in ulcerative colitis?" Clinical Gastroenterology and Hepatology, vol. 12, no. 6, pp. 929. e2-934. e2, 2014.
10. K. Geboes, R. Riddell, A. Ost, B. Jensfelt, T. Persson, and R. Löfberg, "A reproducible grading scale for histological assessment of inflammation in ulcerative colitis, " Gut, vol. 47, no. 3, pp. 404-409, 2000.
11. C. H. Choi, S. A. Jung, B. I. Lee, K. M. Lee, J. S. Kim, and D. S. Han, "Diagnostic guideline of ulcerative colitis, " The Korean Journal of Gastroenterology, vol. 53, no. 3, pp. 145-160, 2009.
12. L. Rosenberg, K. S. Nanda, T. Zenlea, et al., "Histologic markers of inflammation in patients with ulcerative colitis in clinical remission, " Clinical Gastroenterology andHepatology, vol. 11, no. 8, pp. 991-996, 2013.
13. T. Bessissow, B. Lemmens, M. Ferrante, et al., "Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing, " The American Journal of Gastroenterology, vol. 107, no. 11, pp. 1684-1692, 2012.
14. A. M. Schoepfer, C. Beglinger, A. Straumann, M. Trummler, P. Renzulli, and F. Seibold, "Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes, " Inflammatory Bowel Diseases, vol. 15, no. 12, pp. 1851-1858, 2009.
15. S. Karoui, S. Laz, M. Serghini, N. Bibani, J. Boubaker, and A. Filali, "Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis, " Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1801-1805, 2011.
16. T. Osada, T. Ohkusa, I. Okayasu, et al., "Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis, " Journal of Gastroenterology and Hepatology, vol. 23, supplement 2, pp. S262-S267, 2008.
17. K. H. Lok, C. H. Ng, H. G. Hung, K. F. Li, K. K. Li, and M. L. Szeto, "Correlation of serum biomarkers with clinical severity andmucosal inflammation in Chinese ulcerative colitis patients, " Journal of DigestiveDiseases, vol. 9, no. 4, pp. 219-224, 2008.
18. C. A. Solem, E. V. Loftus Jr., W. J. Tremaine, W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn, "Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease, " Inflammatory Bowel Diseases, vol. 11, no. 8, pp. 707-712, 2005.
19. P. Rutgeerts, W. J. Sandborn, B. G. Feagan, et al., "Infliximab for induction and maintenance therapy for ulcerative colitis, " The New England Journal of Medicine, vol. 353, no. 23, pp. 2462-2476, 2005.
20. W. J. Sandborn, G. Van Assche, W. Reinisch, et al., "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, " Gastroenterology, vol. 142, no. 2, pp. 257-265. e3, 2012.
21. S. P. L. Travis, D. Schnell, P. Krzeski, et al., "Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), " Gut, vol. 61, no. 4, pp. 535-542, 2012.
22. T. de Lange, S. Larsen, and L. Aabakken, "Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis, " BMC Gastroenterology, vol. 4, article 9, 2004.
23. S. Vermeire, G. Van Assche, and P. Rutgeerts, "The role of Creactive protein as an inflammatory marker in gastrointestinal diseases, " Nature Clinical Practice Gastroenterology & Hepatology, vol. 2, no. 12, pp. 580-586, 2005.
24. A. D. Rodgers and A. G. Cummins, "CRP correlates with clinical score in ulcerative colitis but not in Crohns disease, " Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2063-2068, 2007.
25. E. A. Fagan, R. F. Dyck, P. N. Maton, et al., "Serum levels of C-reactive protein in Crohns disease and ulcerative colitis, " European Journal of Clinical Investigation, vol. 12, no. 4, pp. 351-359, 1982.
26. M. Henriksen, J. Jahnsen, I. Lygren, et al., "C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, " Gut, vol. 57, no. 11, pp. 1518-1523, 2008.
27. J. D. Lewis, S. Chuai, L. Nessel, G. R. Lichtenstein, F. N. Aberra, and J. H. Ellenberg, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis, " Inflammatory Bowel Diseases, vol. 14, no. 12, pp. 1660-1666, 2008.
28. D. Turner, C. H. Seow, G. R. Greenberg, A. M. Griffiths, M. S. Silverberg, and A. H. Steinhart, "A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis, " Clinical Gastroenterology and Hepatology, vol. 7, no. 10, pp. 1081-1088, 2009.
29. S. C. Truelove and W. C. Richards, "Biopsy studies in ulcerative colitis, " British Medical Journal, vol. 1, no. 4979, pp. 1315-1318, 1956.
30. B. Isgar, M. Harman, M. D. Kaye, and P. J. Whorwell, "Symptoms of irritable bowel syndrome in ulcerative colitis in remission, " Gut, vol. 24, no. 3, pp. 190-192, 1983.
31. I. M. Minderhoud, B. Oldenburg, J. A. Wismeijer, G. P. V. B. Henegouwen, and A. J. P. M. Smout, "IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior, " Digestive Diseases and Sciences, vol. 49, no. 3, pp. 469-474, 2004.
32. N. Fukuba, S. Ishihara, Y. Tada, et al., "Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study, " Scandinavian Journal of Gastroenterology, vol. 49, no. 6, pp. 674-680, 2014.
33. J.-Y. Xiang, Q. Ouyang, G.-D. Li, and N.-P. Xiao, "Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis, "World Journal of Gastroenterology, vol. 14, no. 1, pp. 53-57, 2008.
34. I. K. Onal, Y. Beyazit, B. Sener, et al., "The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis, " Turkish Journal of Gastroenterology, vol. 23, no. 5, pp. 509-514, 2012.